The treatment-naive microbiome in new-onset Crohn's disease - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 12;15(3):382-392.
doi: 10.1016/j.chom.2014.02.005.

The treatment-naive microbiome in new-onset Crohn's disease

Affiliations

The treatment-naive microbiome in new-onset Crohn's disease

Dirk Gevers et al. Cell Host Microbe. .

Abstract

Inflammatory bowel diseases (IBDs), including Crohn's disease (CD), are genetically linked to host pathways that implicate an underlying role for aberrant immune responses to intestinal microbiota. However, patterns of gut microbiome dysbiosis in IBD patients are inconsistent among published studies. Using samples from multiple gastrointestinal locations collected prior to treatment in new-onset cases, we studied the microbiome in the largest pediatric CD cohort to date. An axis defined by an increased abundance in bacteria which include Enterobacteriaceae, Pasteurellacaea, Veillonellaceae, and Fusobacteriaceae, and decreased abundance in Erysipelotrichales, Bacteroidales, and Clostridiales, correlates strongly with disease status. Microbiome comparison between CD patients with and without antibiotic exposure indicates that antibiotic use amplifies the microbial dysbiosis associated with CD. Comparing the microbial signatures between the ileum, the rectum, and fecal samples indicates that at this early stage of disease, assessing the rectal mucosal-associated microbiome offers unique potential for convenient and early diagnosis of CD.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Most differential taxa in pediatric CD
(A) A set of principal coordinate plots of the unweighted UniFrac distance, with each sample colored either by the disease phenotype (left), alpha diversity (middle), or sample type (right). PC1, PC2, and PC3 represent the top three principal coordinates that captured most of the diversity, with the fraction of diversity captured by that coordinate shown in percent. (B) Differences in abundance are shown for the taxonomic biomarkers that were detected using a multivariate statistical approach (see Experimental Procedures and Table S2). The fold change for each taxon was calculated by dividing the mean abundance in the cases by that of the controls. Several taxonomic biomarkers measured at both the ileal and rectal sites were found to be significantly correlated with disease phenotype; however, most of that microbial signal was lost in the stool samples. The fraction of patients that were on antibiotics during sample collection was considered as an individual subtype, due to the large confounding impact antibiotic exposure causes on the microbial composition (see Table S2). The left shows cases without antibiotic treatment, and the right includes the fraction of cases (10%) that were under antibiotic pressure at sampling. The taxa at the top are increased in disease state, whereas the taxa at the bottom follow an opposite trend. Apparent missing bars are cases in which there is no difference, or fold change equals 1. Use of antibiotics does impact the microbial composition by tipping the microbial community further towards a dysbiotic state, and has a differential impact on the taxa, depending on organism and sampling site. Related to Figure S1, Table S1.
Figure 2
Figure 2. The Microbial Dysbiosis index characterizes CD severity
(A) A correlation network was inferred for the ileal microbiota compositions using CCREPE with a checkerboard score, indicating a strong co-occurrence between taxa of the same disease-associated behavior and a co-exclusion between taxa of a different behavior. Nodes represent the different taxa, and color corresponds to their behavior in disease, with green for those decreased in CD and red for those increased in CD. Edges between nodes represent correlations between the nodes they connect, with edge colors of dark and light grey indicating positive and negative correlations, respectively. For clarity, only edges corresponding to correlations whose similarity was less than 0.3 are shown. (B) Scatterplot of the arcsine square root transformed abundances of all summed abundances for the taxa increased (top) or decreased (bottom) in CD, versus the pediatric CD activity index (PCDAI (Hyams et al., 1991)) as a measure for disease severity. (C) Scatter density plot of the species richness (Chao1, (Chao et al., 2006)) versus the Microbial Dysbiosis index (MD-index) for each sample. The increase in blue color (white to dark blue) reflects the density of the scatter plot. The MD-index is defined as the log of [total abundance in organisms increased in CD] over [total abundance of organisms decreased in CD] (organisms listed in Fig 1A), and is intended as an overall summary statistic for the microbial dysbiosis described in more detail in panel A. In samples with a high MD-index (> 1), a strong reduction in the species richness was observed. (D) A principal coordinate plot of the unweighted UniFrac distance, colored by the MD-index. Sqrt, square root.Related to Figure S2, Table S2.
Figure 3
Figure 3. Comparative genomics of CD biomarkers
The KEGG metabolic pathways that differentiate the species by behavior in disease state are shown as a heatmap. A selection of reference genomes that are representative for the species increased or decreased with disease were obtained from IMG (JGI), and biomarker detection was performed on their gene content at the level of KEGG pathways. Several were statistically significant (Wilcoxon, p < 10e-8) and are visualized here. Related to Table S2.
Figure 4
Figure 4. Disease classification performs well on biopsy-associated microbiome profiles
(A-C) For each of the three sample types, including terminal ileum biopsy (A), rectum biopsy (B), and stool sample (C), we evaluated the accuracy of disease classification using L1 penalized logistic regression with ROC curves representing the results. Dashed lines show the mean performance obtained when genus-level features were used, and the surrounding grey area is the 95% confidence interval. Terminal ileum biopsies performed best (AUC = 0.85), closely matched by the rectum biopsies (AUC = 0.78). However, the classifier based on the stool samples collected at the time of the diagnosis performs less well (AUC = 0.66), and with low consistency (large confidence interval). (D) The intra-subject diversity in microbiome composition was determined for all pairwise sample type combinations. Both biopsy samples were found to be highly similar, whereas the stool sample was quite diverse. Further, we also compared whether disease location would impact the intra-subject diversity between the two tissue biopsy locations. The location of the disease, ileal (L1), colonic (L2), or ileocolonic (L3), did not significantly disrupt the similarity between the two intra-subject mucosal-associated microbiota. Also, no biomarker was detected allowing us to distinguish these disease sub-phenotypes. Related to Figure S3.
Figure 5
Figure 5. A view of the microbial composition across different IBD cohorts
We combined microbial profiles obtained for 1,742 subjects from three different IBD cohorts and generated a set of principal coordinate plots of the unweighted UniFrac distance, where each sample was colored by (A) cohort, (B) disease type, (C) MD-index, or (D) species richness (Chao1). From this combined view, it is clear that the first principal coordinate (PC1) stratifies the samples by species richness, which is negatively correlated with MD-index, and that the second principal coordinate (PC2) is largely affected by cohort. Disease phenotype is no obvious driver for sample clustering.

Comment in

Similar articles

Cited by

References

    1. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun. 2009;77:2367–2375. - PMC - PubMed
    1. Belkaid Y, Naik S. Compartmentalized and systemic control of tissue immunity by commensals. Nat Immunol. 2013;14:646–653. - PMC - PubMed
    1. Chao A, Chazdon RL, Colwell RK, Shen TJ. Abundance-based similarity indices and their estimation when there are unseen species in samples. Biometrics. 2006;62:361–371. - PubMed
    1. Chavan RS, Pannaraj PS, Luna RA, Szabo S, Adesina A, Versalovic J, Krance RA, Kennedy-Nasser AA. Significant morbidity and mortality attributable to rothia mucilaginosa infections in children with hematological malignancies or following hematopoietic stem cell transplantation. Pediatr Hematol Oncol. 2013;30:445–454. - PubMed
    1. HMP Consortium A framework for human microbiome research. Nature. 2012;486:215–221. - PMC - PubMed

Publication types